SCHEDULE 13G

CUSIP No.

05153U107

Names of Reporting Persons

Advent Life Sciences LLP

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,023,857.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,023,857.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,023,857.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

3.258 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.

SCHEDULE 13G

CUSIP No.

05153U107

Names of Reporting Persons

Advent Life Sciences Fund I LP

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,023,857.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,023,857.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,023,857.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

3.258 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

05153U107

Names of Reporting Persons

Rajesh Parekh, Ph.D.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,023,857.00
7	Sole Dispositive Power 48,000.00
8	Shared Dispositive Power 2,071,857.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,071,857.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

3.335 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

05153U107

Names of Reporting Persons

Advent Life Sciences Fund III LP

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,023,857.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,023,857.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,023,857.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

3.258 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

05153U107

Names of Reporting Persons

ALS III Carry and Co-Invest LP

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,023,857.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,023,857.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,023,857.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

3.258 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

05153U107

Names of Reporting Persons

Advent-Harrington Impact Fund LP

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,023,857.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,023,857.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,023,857.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

3.258 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Aura Biosciences, Inc.

(b)

Address of issuer's principal executive offices:

80 Guest Street, Boston, MASSACHUSETTS 2135

Item 2.

(a)

Name of person filing:

Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP and Rajesh Parekh, Ph.D.

(b)

Address or principal business office or, if none, residence:

27 Fitzroy Square, London, United Kingdom W1T 6ES

(c)

Citizenship:

Citizenship: Advent Life Sciences LLP ("Advent") is a limited liability partnership organized under the laws of the United Kingdom. Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, and Advent-Harrington Impact Fund LP (collectively, the "Advent Funds") are limited partnerships organized under the laws of the United Kingdom. Dr. Parekh is a citizen of the United Kingdom.

(d)

Title of class of securities:

Common Stock, par value $0.00001 per share

(e)

CUSIP No.:

05153U107

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of each of Advent and the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.

(b)

Percent of class:

Advent Life Sciences LLP and the Advent Funds 3.258%; Dr. Parekh 3.335%.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or to direct the vote:

By virtue of the relationships set forth herein, Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of Advent and each of the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.

(iii) Sole power to dispose or to direct the disposition of:

Advent Life Sciences LLP and the Advent Funds 0% and Dr. Parekh 0.07727%,

(iv) Shared power to dispose or to direct the disposition of:

By virtue of the relationships set forth herein, Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of each of Advent and the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.

Item 5.

Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Advent Life Sciences LLP

Signature:	/s/Rajesh Parekh, Ph.D.
Name/Title:	General Partner of Advent Life Sciences LLP
Date:	02/13/2026

Advent Life Sciences Fund I LP

Signature:	/s/Rajesh Parekh, Ph.D.
Name/Title:	General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund I LP
Date:	02/13/2026

Rajesh Parekh, Ph.D.

Signature:	/s/Rajesh Parekh, Ph.D.
Name/Title:	/s/Rajesh Parekh, Ph.D.
Date:	02/13/2026

Advent Life Sciences Fund III LP

Signature:	/s/Rajesh Parekh, Ph.D.
Name/Title:	General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund III LP
Date:	02/13/2026

ALS III Carry and Co-Invest LP

Signature:	/s/Rajesh Parekh, Ph.D.
Name/Title:	General Partner of Advent Life Sciences LLP acting in its capacity as Manager of ALS III Carry and Co-Invest LP
Date:	02/13/2026

Advent-Harrington Impact Fund LP

Signature:	/s/Rajesh Parekh, Ph.D.
Name/Title:	General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent-Harrington Impact Fund LP
Date:	02/13/2026

Comments accompanying signature: See comments re: reporting persons and signature information.

Exhibit Information

Agreement Regarding the Joint Filing of Schedule 13G dated February 11, 2022 (as filed by the Reporting Persons on Schedule 13G on February 14, 2022).